Literature DB >> 22930681

Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion.

Won June Lee1, Min Ho Kang, Mincheol Seong, Hee Yoon Cho.   

Abstract

AIMS: The involvement of cytokines in the aqueous humour is important in the development and progression of diabetic macular oedema (DMO) and macular oedema (MO) due to branch retinal vein occlusion (BRVO-MO). In this study, the concentrations of cytokines in the aqueous humour of eyes with DMO and BRVO-MO were measured and compared.
METHODS: Prospective, observational case series. Aqueous samples were obtained from 18 eyes with DMO (DMO group), 12 eyes with BRVO-MO (BRVO-MO group), and 16 normal eyes (control group). The aqueous levels of cytokines, including interleukin (IL)-2, IL-5, IL-6, IL-8, IL-12p70, IL-13, monocytochemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), platelet-derived growth factor-AA (PDGF)-AA, transforming growth factor-α (TGF-α), interferon-γ (IFN-γ), epidermal growth factor, fibroblast growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF), were measured.
RESULTS: The aqueous levels of IL-8, MCP-1, PDGF-AA and VEGF were higher, and IL-13 was lower in the DMO group compared with the control group. The aqueous levels of IL-8 and VEGF were higher in the BRVO-MO group than in the control group. Compared with the IL-6 and MCP-1 levels in the BRVO-MO group, those levels were significantly higher in the DMO group. Correlation analyses revealed that IL-8 was positively and IFN-γ was negatively correlated with the severity of MO in the DMO group. In the BRVO-MO group, IL-8 and was positively correlated with severity of MO and retinal ischaemia.
CONCLUSIONS: DMO and BRVO-MO may differ in terms of pathogenesis because the cytokine concentrations in the aqueous humour differ. The results suggest that the inflammatory reaction may be more activated in DMO than in BRVO-MO, and ischaemic insult may play a central role in the development of BRVO-MO.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22930681     DOI: 10.1136/bjophthalmol-2012-301913

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  34 in total

1.  A novel and less invasive technique to assess cytokine profile of vitreous in patients of diabetic macular oedema.

Authors:  G Srividya; M Jain; K Mahalakshmi; S Gayathri; R Raman; N Angayarkanni
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

Review 2.  The role of inflammation in diabetic eye disease.

Authors:  Marina Mesquida; Faye Drawnel; Sascha Fauser
Journal:  Semin Immunopathol       Date:  2019-06-07       Impact factor: 9.623

Review 3.  Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment.

Authors:  Steven F Abcouwer; Thomas W Gardner
Journal:  Ann N Y Acad Sci       Date:  2014-03-27       Impact factor: 5.691

4.  Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.

Authors:  Francesco Pichi; Ahmed Mohammed Elbarky; Tarek Roshdy Elhamaky
Journal:  Int Ophthalmol       Date:  2017-12-22       Impact factor: 2.031

Review 5.  [Unmet research and developmental needs in ophthalmology : A consensus-based road map of the European Vision Institute for 2019-2025].

Authors:  C Cursiefen; F Cordeiro; J Cunha-Vaz; T Wheeler-Schilling; H P N Scholl
Journal:  Ophthalmologe       Date:  2019-09       Impact factor: 1.059

6.  Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema.

Authors:  Seung-Young Yu; Dong Heun Nam; Dae Yeong Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-10-13       Impact factor: 3.117

7.  Angiogenic Factors and Cytokines in Diabetic Retinopathy.

Authors:  Steven F Abcouwer
Journal:  J Clin Cell Immunol       Date:  2013

Review 8.  'Statins in retinal disease'.

Authors:  Ahmed Al-Janabi; Sue Lightman; Oren Tomkins-Netzer
Journal:  Eye (Lond)       Date:  2018-03-20       Impact factor: 3.775

9.  Pro-permeability Factors in Diabetic Macular Edema; the Diabetic Macular Edema Treated With Ozurdex Trial.

Authors:  Peter A Campochiaro; Gulnar Hafiz; Tahreem A Mir; Adrienne W Scott; Ingrid Zimmer-Galler; Syed M Shah; Adam S Wenick; Christopher J Brady; Ian Han; Lingmin He; Roomasa Channa; David Poon; Catherine Meyerle; Mary Beth Aronow; Akrit Sodhi; James T Handa; Saleema Kherani; Yong Han; Raafay Sophie; Guohua Wang; Jiang Qian
Journal:  Am J Ophthalmol       Date:  2016-04-27       Impact factor: 5.258

10.  Aqueous humour concentrations of TGF-β, PLGF and FGF-1 and total retinal blood flow in patients with early non-proliferative diabetic retinopathy.

Authors:  Lee-Anne Khuu; Faryan Tayyari; Jeremy M Sivak; John G Flanagan; Shaun Singer; Michael H Brent; David Huang; Ou Tan; Christopher Hudson
Journal:  Acta Ophthalmol       Date:  2016-09-28       Impact factor: 3.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.